secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-062241
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Vanda's HETLIOZ insomnia sNDA
---------------------------------------------------------------------

- Received CRL on March 4, 2024 for HETLIOZ (tasimelteon) to treat insomnia with sleep initiation difficulties.
- FDA stated deficiencies precluding approval; sNDA cannot be approved in present form.
- Vanda reviewing CRL and evaluating next steps; no specific financial impact disclosed.
- PDUFA date was March 4, 2024; FDA had flagged deficiencies on February 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524062241/0001193125-24-062241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524062241/d764198d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-062241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer